CFDA proposes 12-year data exclusivity for innovative biologics

China FDA released an interim document stating that innovative therapeutic biologics will receive 12 years of data exclusivity from the date

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE